Skip to main content
PMC home page
Gut logoLink to Gut
. 1993 Aug;34(8):1081–1085. doi: 10.1136/gut.34.8.1081

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

W R Connell 1, M A Kamm 1, J K Ritchie 1, J E Lennard-Jones 1
PMCID: PMC1374358  PMID: 8174958

Abstract

Myelosuppression is an important and potentially lethal complication of azathioprine treatment. The blood count has been reviewed in all patients treated with azathioprine for inflammatory bowel disease over 27 years in one hospital. Altogether 739 patients (422 with Crohn's disease, 284 with ulcerative colitis, and 33 with indeterminate colitis) were treated with 2 mg/kg/day azathioprine for a median of 12.5 months (range 0.5-132) between 1964 and 1991. Full blood counts were performed monthly for the duration of treatment. In 37 patients (5%) who developed bone marrow toxicity, the drug was withdrawn or the dose reduced. Thirty two of these patients were asymptomatic and five developed symptoms. Leucopenia (white blood count less than 3.0 x 10g/l) occurred in 28 (3.8%) patients, in nine of whom it was severe (white blood count < 2.0 x 10(9)/l). Of these nine patients, three were pancytopenic: two died from sepsis and the other had pneumonia but recovered. A further two patients with severe leucopenia developed a mild upper respiratory infection only. Thrombocytopenia (platelet count < 100,000 x 10(6)/l) in 15 patients was associated with leucopenia in six and developed in isolation in a further nine (total 2%). Isolated thrombocytopenia was never clinically severe. Myelotoxicity from azathioprine developed at any time during drug treatment (range 2 weeks-11 years after starting the drug) and occurred either suddenly or over several months. Bone marrow suppression as a result of azathioprine treatment is uncommon when a moderate dose is used, but is potentially severe. Leucopenia is the commonest and most important haematological complication. Regular monitoring of the full blood count is recommended during treatment.

Full text

PDF
1081

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacon B. R., Treuhaft W. H., Goodman A. M. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Med. 1981 Feb;141(2):223–226. [PubMed] [Google Scholar]
  2. Bunch T. W., O'Duffy J. D. Disease-modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc. 1980 Mar;55(3):161–179. [PubMed] [Google Scholar]
  3. Burke D. A., Dixon M. F., Axon A. T. Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia. J Clin Gastroenterol. 1989 Jun;11(3):327–330. [PubMed] [Google Scholar]
  4. Chocair P. R., Duley J. A., Simmonds H. A., Cameron J. S. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. 1992 May;53(5):1051–1056. doi: 10.1097/00007890-199205000-00016. [DOI] [PubMed] [Google Scholar]
  5. Evans W. E., Horner M., Chu Y. Q., Kalwinsky D., Roberts W. M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991 Dec;119(6):985–989. doi: 10.1016/s0022-3476(05)83063-x. [DOI] [PubMed] [Google Scholar]
  6. Goldstein F. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J Clin Gastroenterol. 1987 Dec;9(6):654–658. doi: 10.1097/00004836-198712000-00009. [DOI] [PubMed] [Google Scholar]
  7. Goldstein F. Maintenance treatment for Crohn's disease: has the time arrived? Am J Gastroenterol. 1992 May;87(5):551–556. [PubMed] [Google Scholar]
  8. Jeurissen M. E., Boerbooms A. M., van de Putte L. B. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis. 1988 Jun;47(6):503–505. doi: 10.1136/ard.47.6.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jewell D. P., Truelove S. C. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974 Dec 14;4(5945):627–630. doi: 10.1136/bmj.4.5945.627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jones F. A., Lennard-Jones J. E., Hinton J. M., Reeves W. G. Dangers of immunosuppressive drugs in ulcerative colitis. Br Med J. 1966 Jun 4;1(5500):1418–1418. doi: 10.1136/bmj.1.5500.1418-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kinlen L. J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. doi: 10.1016/0002-9343(85)90245-1. [DOI] [PubMed] [Google Scholar]
  12. Kirk A. P., Lennard-Jones J. E. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982 May 1;284(6325):1291–1292. doi: 10.1136/bmj.284.6325.1291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klein M., Binder H. J., Mitchell M., Aaronson R., Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology. 1974 May;66(5):916–922. [PubMed] [Google Scholar]
  14. Kölle G. Knochenmarksschädigung bei immunsuppressiver Therapie der juvenilen rheumatoiden Arthritis und des Still-Syndroms mit Azathioprin. Dtsch Med Wochenschr. 1969 Oct 31;94(44):2268–2273. doi: 10.1055/s-0028-1110429. [DOI] [PubMed] [Google Scholar]
  15. Lawson D. H., Lovatt G. E., Gurton C. S., Hennings R. C. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev. 1984 Autumn;3(3):161–171. [PubMed] [Google Scholar]
  16. Lennard L., Rees C. A., Lilleyman J. S., Maddocks J. L. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983 Oct;16(4):359–363. doi: 10.1111/j.1365-2125.1983.tb02178.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lennard L., Van Loon J. A., Weinshilboum R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989 Aug;46(2):149–154. doi: 10.1038/clpt.1989.119. [DOI] [PubMed] [Google Scholar]
  18. McGrath B. P., Ibels L. S., Raik E., Hargrave M. J. Erythroid toxicity of azathioprin. Macrocytosis and selective marrow hypoplasis. Q J Med. 1975 Jan;44(173):57–63. [PubMed] [Google Scholar]
  19. Nyman M., Hansson I., Eriksson S. Long-term immunosuppressive treatment in Crohn's disease. Scand J Gastroenterol. 1985 Dec;20(10):1197–1203. doi: 10.3109/00365528509089276. [DOI] [PubMed] [Google Scholar]
  20. O'Brien J. J., Bayless T. M., Bayless J. A. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991 Jul;101(1):39–46. doi: 10.1016/0016-5085(91)90457-v. [DOI] [PubMed] [Google Scholar]
  21. O'Donoghue D. P., Dawson A. M., Powell-Tuck J., Bown R. L., Lennard-Jones J. E. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978 Nov 4;2(8097):955–957. doi: 10.1016/s0140-6736(78)92524-2. [DOI] [PubMed] [Google Scholar]
  22. Old C. W., Flannery E. P., Grogan T. M., Stone W. H., San Antonio R. P. Azathioprine-induced pure red blood cell aplasia. JAMA. 1978 Aug 11;240(6):552–554. [PubMed] [Google Scholar]
  23. Present D. H., Meltzer S. J., Krumholz M. P., Wolke A., Korelitz B. I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989 Oct 15;111(8):641–649. doi: 10.7326/0003-4819-111-8-641. [DOI] [PubMed] [Google Scholar]
  24. Rhodes J., Bainton D., Beck P., Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971 Dec 11;2(7737):1273–1276. doi: 10.1016/s0140-6736(71)90598-8. [DOI] [PubMed] [Google Scholar]
  25. Singleton J. W., Law D. H., Kelley M. L., Jr, Mekhjian H. S., Sturdevant R. A. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979 Oct;77(4 Pt 2):870–882. [PubMed] [Google Scholar]
  26. Summers R. W., Switz D. M., Sessions J. T., Jr, Becktel J. M., Best W. R., Kern F., Jr, Singleton J. W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979 Oct;77(4 Pt 2):847–869. [PubMed] [Google Scholar]
  27. Theodor E., Niv Y., Bat L. Imuran in the treatment of ulcerative colitis. Am J Gastroenterol. 1981 Sep;76(3):262–266. [PubMed] [Google Scholar]
  28. Van Loon J. A., Weinshilboum R. M. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet. 1982 Aug;20(7-8):637–658. doi: 10.1007/BF00483962. [DOI] [PubMed] [Google Scholar]
  29. Van Scoik K. G., Johnson C. A., Porter W. R. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev. 1985;16(1-2):157–174. doi: 10.3109/03602538508991433. [DOI] [PubMed] [Google Scholar]
  30. Whisnant J. K., Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis. 1982;41 (Suppl 1):44–47. doi: 10.1136/ard.41.suppl_1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wickramasinghe S. N., Dodsworth H., Rault R. M., Hulme B. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation. 1974 Nov;18(5):443–446. doi: 10.1097/00007890-197411000-00009. [DOI] [PubMed] [Google Scholar]
  32. Willoughby J. M., Beckett J., Kumar P. J., Dawson A. M. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971 Oct 30;2(7731):944–947. doi: 10.1016/s0140-6736(71)90268-6. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES